Lacosamide
( DrugBank: Lacosamide / KEGG DRUG: Lacosamide )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 3 |
| 46 | Malignant rheumatoid arthritis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 149 | Hemiconvulsion hemiplegia epilepsy syndrome | 1 |
| 298 | Hereditary pancreatitis | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 867 / Drugs : 820 - (DrugBank : 185) / Drug target genes : 189 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. Malignant rheumatoid arthritis
Clinical trials : 4,743 / Drugs : 3,042 - (DrugBank : 389) / Drug target genes : 205 - Drug target pathways : 253
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
149. Hemiconvulsion hemiplegia epilepsy syndrome
Clinical trials : 55 / Drugs : 61 - (DrugBank : 17) / Drug target genes : 19 - Drug target pathways : 40
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
298. Hereditary pancreatitis
Clinical trials : 126 / Drugs : 210 - (DrugBank : 59) / Drug target genes : 65 - Drug target pathways : 161
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|